TP53 and breast carcinoma: Therefore, we pharmacologically inhibited MDM4 using a pseudourea derivative XI-001 in the lumenal breast cancer cell line MCF7 carrying a wild type TP53 gene and, indeed, observed a strong re-expression of the TP53 protein (Supplementary Figure 3).